This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors

This study is currently recruiting participants.
See Contacts and Locations
Verified February 2017 by South Plains Oncology Consortium
Information provided by (Responsible Party):
South Plains Oncology Consortium Identifier:
First received: December 11, 2013
Last updated: February 2, 2017
Last verified: February 2017
This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.

Condition Intervention Phase
Recurrent or Refractory Solid Tumors Ewing Sarcoma Rhabdomyosarcoma Neuroblastoma Osteosarcoma Drug: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

Resource links provided by NLM:

Further study details as provided by South Plains Oncology Consortium:

Primary Outcome Measures:
  • To determine the Maximum Tolerated Dose (MTD) of MM-398 in combination with intravenous cyclophosphamide by assessing the occurrence of dose limiting toxicities [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • Measurement of plasma levels of study drug to determine the pharmacokinetic properties of MM-398 in combination with cyclophosphamide [ Time Frame: 12 months ]

Estimated Enrollment: 30
Study Start Date: December 2013
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MM-398 + cyclophosphamide Drug: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide


Ages Eligible for Study:   12 Months to 20 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically-confirmed Ewing sarcoma, rhabdomyosarcoma, neuroblastoma, or osteosarcoma
  • Disease progression after prior therapy in locally advanced or metastatic setting
  • Measurable or evaluable disease based on the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria
  • Age 12 months to <21 years
  • Adequate bone marrow reserves, hepatic function, and renal function
  • Recovered from effects of any prior surgery or cancer therapy
  • Patients 18 years or older will provide written consent. A parent or legal guardian of a patient <18 years of age will provide informed consent and patients 11 to 18 years of age will provide written assent or as per participating institutional policy.

Exclusion Criteria:

  • Clinically significant gastrointestinal disorders
  • NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure
  • Active infection or unexplained fever
  • Known hypersensitivity to any of the components of MM-398 or other liposomal products
  • Recent Investigational therapy
  • Pregnant or breast feeding; females of child-bearing potential must test negative for pregnancy at the time of enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02013336

Contact: Amanda Knight, RN, BSN, CCRP 806-743-2690

United States, Oklahoma
University Of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States
Contact: Susan Heavner         
United States, Texas
UT Southwestern Recruiting
Dallas, Texas, United States
Contact: Alison Patterson         
Not yet recruiting
Houston, Texas, United States
Texas Tech University Health Sciences Center Not yet recruiting
Lubbock, Texas, United States, 79430
United States, Wisconsin
Midwest Children's Hospital Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Adam Fiebelkorn         
Sponsors and Collaborators
South Plains Oncology Consortium
Study Chair: Paul Harker-Murray, MD Midwest Children's Hospital
  More Information

Responsible Party: South Plains Oncology Consortium Identifier: NCT02013336     History of Changes
Other Study ID Numbers: SPOC-2012-001
Study First Received: December 11, 2013
Last Updated: February 2, 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by South Plains Oncology Consortium:

Additional relevant MeSH terms:
Sarcoma, Ewing
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms, Muscle Tissue
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on August 17, 2017